Chlorpromazine

Product Description

Chlorpromazine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) and other psychotic disorders (conditions that cause difficulty telling the difference between things or ideas that are real and things or ideas that are not real) and to treat the symptoms of mania (frenzied, abnormally excited mood) in people who have bipolar disorder (manic depressive disorder; a condition that causes episodes of mania, episodes of depression, and other abnormal moods). Chlorpromazine is also used to treat severe behavior problems such as explosive, aggressive behavior and hyperactivity in children 1 to 12 years of age. Chlorpromazine is also used to control nausea and vomiting, to relieve hiccups that have lasted one month or longer, and to relieve restlessness and nervousness that may occur just before surgery. Chlorpromazine is also used to treat acute intermittent porphyria (condition in which certain natural substances build up in the body and cause stomach pain, changes in thinking and behavior, and other symptoms). Chlorpromazine is also used along with other medications to treat tetanus (a serious infection that may cause tightening of the muscles, especially the jaw muscle). Chlorpromazine is in a class of medications called conventional antipsychotics. It works by changing the activity of certain natural substances in the brain and other parts of the body. (Sourced from: https://medlineplus.gov/druginfo/meds/a682040.html)

Mechanisms of Action: ADRA1A Inhibitor,ADRA1B Inhibitor,ADRA1D Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Lithuania | Malaysia | Malta | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Serbia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Cycle
Company Location:
Company CEO:
Additonal Commercial Interests: None